OCQUILA
DEAD

Serial Number

77673792

Owner

Oxford BioMedica (UK) Limited

Attorney

Howard N. Aronson

Filing Date

Feb 19, 2009

Add to watchlist:

No watchlists yet
View on USPTO

OCQUILA Trademark

Serial Number: 77673792 • Registration: 3949710

OCQUILA is a trademark filed by Oxford BioMedica (UK) Limited on February 19, 2009. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Oxford BioMedica (UK) Limited (3 trademarks)

Transport Way
Oxford OX4 6LT , GB

Entity Type: 99

Trademark Details

Filing Date

February 19, 2009

Registration Date

April 26, 2011

Published for Opposition

February 8, 2011

Cancellation Date

December 1, 2017

Goods & Services

Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical purposes in connection with gene therapy, pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, and manufacturing preparations for viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; biochemical and chemical preparations for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes

Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; biochemicals, namely, polypeptides for in vitro research use; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory and scientific research and development use in biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, all of the foregoing for in-vivo use

Medical services; advisory services relating to vaccination regimens; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, in humans and animals, and advisory services relating to the use of pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals

Instruments and apparatus for the administration of pharmaceutical, gene therapy and/or vaccine preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes

Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development of new products in the field of biotechnology, advisory services relating to the research and development of gene therapy products and clinical trials, conducting clinical trials

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 1, 2017 C8..
REGISTERED-PRINCIPAL REGISTER
Apr 26, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 8, 2011 NPUB
PUBLISHED FOR OPPOSITION
Feb 8, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 6, 2011 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 5, 2011 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 5, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 5, 2011 CRFA
ASSIGNED TO LIE
Jan 4, 2011 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 7, 2010 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jun 7, 2010 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jun 7, 2010 GNSI
SUSPENSION INQUIRY WRITTEN
Jun 7, 2010 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 1, 2009 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 1, 2009 GNSL
SUSPENSION LETTER WRITTEN
Dec 1, 2009 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 20, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 20, 2009 CRFA
ASSIGNED TO LIE
Nov 20, 2009 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 9, 2009 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 18, 2009 GNRN
NON-FINAL ACTION E-MAILED
May 18, 2009 GNRT
NON-FINAL ACTION WRITTEN
May 18, 2009 CNRT
ASSIGNED TO EXAMINER
May 11, 2009 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2009 NWOS
NEW APPLICATION ENTERED
Feb 23, 2009 NWAP